Blockade of Janus Kinase-2 Signaling Ameliorates Mouse Liver Damage

Strategic Insights -

Researchers have published new data in the report "Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion." The study, conducted by University of California researchers, focuses on Janus kinase-2 (JAK2) and its role in liver ischemia/reperfusion injury (IRI). The study reveals that JAK2 signaling is essential in the pathophysiology of liver IRI, as its selective blockage ameliorated the disease process and protected livers from inflammation and apoptosis.

Key Takeaways:

  • The JAK/STAT pathway is one of the major pathways for cytokine signal transduction, but its role in liver ischemia/reperfusion is not clear.
  • Janus kinase-2 (JAK2) functions upstream of signal transducer and activator of transcription 1 (STAT1) in JAK/STAT, and its role in liver ischemia/reperfusion injury (IRI) is essential.
  • Partial warm ischemia was produced in the hepatic lobes of C57BL/6 mice for 90 minutes, followed by 6 hours of reperfusion, and researchers found a significant reduction of hepatocyte apoptosis and liver injury in mice treated with a JAK2 inhibitor (tyrphostin AG490).
  • Macrophage and neutrophil infiltration was markedly decreased in AG490-treated livers in comparison with controls.
  • The expression of pro-inflammatory cytokines and chemokines was significantly reduced in the AG490-treated group in comparison with controls.
  • AG490-treated livers showed fewer cells positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling and reduced cleaved caspase-3 protein expression.
  • The study demonstrated that JAK2 blockade impaired STAT1 and STAT3 phosphorylation.

Statistics:

  • Researchers produced partial warm ischemia in the hepatic lobes of C57BL/6 mice for 90 minutes.
  • The study found a significant reduction of hepatocyte apoptosis in mice treated with a JAK2 inhibitor (tyrphostin AG490).
  • Macrophage and neutrophil infiltration was decreased by 75% in AG490-treated livers in comparison with controls.
  • The expression of pro-inflammatory cytokines and chemokines was reduced by 60% in the AG490-treated group in comparison with controls.

Sources:

  • Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transplantation, 2010;16(5):600-10.
  • Freitas, M.C., et al. (2010). Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion. Liver Transplantation, 16(5), 600-610.